NEW YORK (GenomeWeb) – Amoy Diagnostics today announced a deal with biopharmaceutical firm Canbridge Life Sciences to develop a companion diagnostic for Canbridge's lead product, CAN008.

Amoy will supply its CD95 IHC and CpG2 qPCR kits as part of the deal. CAN008 is a fully human Fc fusion protein, and in a previous Phase II trial conducted in Europe, it demonstrated "significant overall survival benefit" for recurrent glioblastoma multiforme patients with high expression of the CD95 ligand, or low methylation of CD95L promotor CpG2, the companies said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.